US Stock MarketDetailed Quotes

SABS SAB Biotherapeutics

Watchlist
  • 2.6700
  • -0.0400-1.48%
Close Sep 26 16:00 ET
  • 2.6700
  • 0.00000.00%
Post 16:42 ET
24.64MMarket Cap-433P/E (TTM)
Post-Market
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Sep 9 06:02
    NEWS
    $SAB Biotherapeutics (SABS.US)$
    SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
    SAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is progressing to enroll patients with type 1 diabetes in the last cohort of the study.
    Target dose of SAB-142 2.5mg/kg completed with no observation of serum sickness.
    SAB-142 remains on track for a topline Phase 1 data readout by the end of the ye...
    Trytosaveabit
    Trytosaveabit
    May 21 06:16
    News
    $SAB Biotherapeutics (SABS.US)$ Reuters· just
    FDA Provides Clearance to Ind Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
    Jaguar8
    Jaguar8
    May 21 06:15
    $SAB Biotherapeutics (SABS.US)$
    NEWS
    FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
    SAB Biotherapeutics (Nasdaq: SABS) announced that the FDA has cleared its IND application for SAB-142, a type 1 diabetes therapy, to proceed to a Phase 1 clinical trial in the US.
    SAB-142, a human anti-thymocyte immunoglobulin (hIgG), aims to delay the onset or progression of type 1 diabetes. The ongoing HUMAN trial will assess the safety, tolerability, pharmac...
    Trytosaveabit
    Trytosaveabit
    May 20 16:52
    Update
    $SAB Biotherapeutics (SABS.US)$ SAB-142 In addition to the currently approved and ongoing Phase 1, there is plans to bring this program to IND and CTA filings with global regulatory authorities by the mid-2024. As there are unmet medical needs globally for disease-modifying treatments of T1D, they are going to work with global health authorities and file clinical trial applications and clinical trial notifications in other countries to have a global footprint and reach patients with T1D wor...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data